Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 5/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17609589 | 0.81 | TRPV3 (0.53) | TRPV3TRPA1 | |
| SCHEMBL12506975 | 0.80 | CLK4 (0.51) | ABL1MAP4K4CSNK2A1HIPK4CLK4 | |
| SCHEMBL27362246 | 0.72 | TRPV3 (0.63) | TRPV3SCN9A | |
| SCHEMBL29128671 | 0.70 | CLK4 (0.53) | ABL1MAP4K4CSNK2A1HIPK4CLK4 | |
| SCHEMBL17609694 | 0.70 | TRPV3 (0.51) | TRPV3SCN9AMAP4K4 | |
| SCHEMBL13680557 | 0.70 | TRPV3 (0.51) | TRPV3SCN9A | |
| SCHEMBL21861674 | 0.70 | TRPA1 (0.50) | TRPA1 | |
| SCHEMBL12538603 | 0.68 | TRPV3 (0.46) | TRPV3SCN9A | |
| SCHEMBL2578961 | 0.68 | ALDH1A1 (0.71) | — | |
| SCHEMBL17609549 | 0.68 | TRPA1 (0.52) | TRPV3TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193880-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3193880-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2020-03-25 | — | — | EP | disclosed |
| US-10519158-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-10519158-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190330212-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2019-10-31 | — | — | US | disclosed |
| US-20190330212-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2019-10-31 | — | — | US | disclosed |
| US-10221177-B2 | Inhibiting the transient receptor potential A1 ion channel | HYDRA BIOSCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221177-B2 | Inhibiting the transient receptor potential A1 ion channel | HYDRA BIOSCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2017-09-28 | — | — | US | disclosed |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2017-09-28 | — | — | US | disclosed |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2017-09-28 | — | — | US | disclosed |
| EP-3193880-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | Hydra Biosciences, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044792-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519158-B2 | Inhibiting the transient receptor potential A1 ion channel | TRPV1, TRPA1, TRPV2 | TRPV3 4/4885TRPA1 2/4885HIF1A 537/4885 |
| US-10221177-B2 | Inhibiting the transient receptor potential A1 ion channel | TRPV1, TRPA1, TRPV2 | TRPV3 4/4885TRPA1 2/4885HIF1A 537/4885 |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | TRPV1, TRPA1, TRPV2 | TRPV3 4/4885TRPA1 2/4885HIF1A 537/4885 |
| US-20190330212-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | TRPV1, TRPA1, TRPV2 | TRPV3 4/4885TRPA1 2/4885HIF1A 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.